Colorectal Cancer Clinical Trials in San Francisco, California

8 studies are recruiting for colorectal cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. LYL273 for Patients With Relapsed or Refractory mCRC

   This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco Medical Center, San Francisco, California

   Locations

   5 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05319314 on ClinicalTrials.gov

2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco (UCSF), San Francisco, California

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

4. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

   This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF, San Francisco, California

   Locations

   10 in total

   Run by

   Cartography Biosciences

   See if you can join NCT07321106 on ClinicalTrials.gov

5. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

   This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF, San Francisco, California

   Locations

   21 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07066657 on ClinicalTrials.gov

6. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   San Francisco Oncology Associates, San Francisco, California

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

7. A Multicenter Cancer Biospecimen Collection Study

   This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Curebase, San Francisco, California

   Run by

   Cofactor Genomics, Inc.

   See if you can join NCT04510129 on ClinicalTrials.gov

8. A Study of IBI363 in Subjects with Advanced Solid Malignancies

   This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco (UCSF), San Francisco, California

   Locations

   9 in total

   Run by

   Innovent Biologics (Suzhou) Co. Ltd.

   See if you can join NCT06281678 on ClinicalTrials.gov